Hylander: I must beg to differ. Before COVID, w
Post# of 36568
(Total Views: 346)
Posted On: 04/06/2021 12:27:14 PM
Hylander:
I must beg to differ. Before COVID, what had GNBT actually produced that generated real, tangible revenue? So many products and services were touted, and none of them ever were discussed after they were promoted. The list? CBD water, Pantheon Medical orthopedic surgical devices/equipment, NGDx -Malaria PF/PV Cassette Test Kit malaria diagnostic kits, buccal insulin delivery, Excellagen, Regentys’ non-surgical hydrogel therapy, Express II Syphilis Treponemal Assay, DME-IQ tablet-based software for orthopedists, or ALTuCELL’s Alginate Microcapsules? Not even a whisper about revenue from any of these in conference calls. That does not even include the services that were being provided (pharmacies, telehealth, etc.). On the other hand, we have the Veneto and Creek Mountain disasters, and the finger of blame led to nothing, as far as shareholders know. There obviously is some significant doubt out there about this company, else the SP would have been and still would be significantly higher.
Then COVID came, and once again, GNBT jumped on the bandwagon. The problem this time is that other companies not only joined in the band, but actually developed something, leading (IMHO) to the fallback position of "we've got a trademarked Complete Vaccine," which may buy a few more months. Or maybe not. Either way, this company is not producing revenue, and with all the above products and services touted over the last few years, the glaring question is...WHY.?
I must beg to differ. Before COVID, what had GNBT actually produced that generated real, tangible revenue? So many products and services were touted, and none of them ever were discussed after they were promoted. The list? CBD water, Pantheon Medical orthopedic surgical devices/equipment, NGDx -Malaria PF/PV Cassette Test Kit malaria diagnostic kits, buccal insulin delivery, Excellagen, Regentys’ non-surgical hydrogel therapy, Express II Syphilis Treponemal Assay, DME-IQ tablet-based software for orthopedists, or ALTuCELL’s Alginate Microcapsules? Not even a whisper about revenue from any of these in conference calls. That does not even include the services that were being provided (pharmacies, telehealth, etc.). On the other hand, we have the Veneto and Creek Mountain disasters, and the finger of blame led to nothing, as far as shareholders know. There obviously is some significant doubt out there about this company, else the SP would have been and still would be significantly higher.
Then COVID came, and once again, GNBT jumped on the bandwagon. The problem this time is that other companies not only joined in the band, but actually developed something, leading (IMHO) to the fallback position of "we've got a trademarked Complete Vaccine," which may buy a few more months. Or maybe not. Either way, this company is not producing revenue, and with all the above products and services touted over the last few years, the glaring question is...WHY.?
(5)
(0)